A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Description

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

Conditions

Alcoholic Hepatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Condition
Alcoholic Hepatitis
Intervention / Treatment

-

Contacts and Locations

Bradenton

Synergry Healthcare, Bradenton, Florida, United States, 34209

Tampa

Florida Health Sciences Center/Tampa General Hospital/USF, Tampa, Florida, United States, 33606

Dallas

The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States, 75203

Houston

UDL Clinical Research, LLC, Houston, Texas, United States, 77057

San Antonio

Methodist Specialty and Transplant Hospital, San Antonio, Texas, United States, 78229

Richmond

Bon Secours Liver Institute of Newport News, Richmond, Virginia, United States, 23221

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult ≥ 21 years old on the day of signing the informed consent form;
  • * Clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the Investigator at screening
  • * Agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment
  • * Ability and willingness to swallow tablets
  • * Willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements
  • * Pregnant, intending to become pregnant (or father a child), or breastfeeding
  • * Current or recent enrollment in another interventional trial in the 30 days prior to screening

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Aldeyra Therapeutics, Inc.,

Study Record Dates

2025-12-31